Clinical Trial Update: Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) [Phase 3]

View source ↗

Summary

Phase 3 trial update on the safety and tolerability of oral OPC-34712 as an adjunctive therapy for adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder
• Mood Disorders

Drugs mentioned

• OPC-34712

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Depressive Disorder, Depression | Phase 3 | Status: COMPLETED | Results posted: 2018-09-17